Metformin for Abdominal Aortic Aneurysm Growth Inhibition

Abdominal Aortic Aneurysm Clinical Trial

— MAAAGI  

Official title:

Metformin for AAA Growth Inhibition, a Randomized Controlled Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04224051
• Other study ID #: MAAAGI
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: February 12, 2020
• Est. completion date: January 2026

Study information

• Verified date: September 2023
• Source: Uppsala University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.

Description:

Subjects with no history of diabetes will be recruited from a cohort of patients with diagnosed AAA and a maximum aortic diameter of 30-49mm for men and 30-44mm for women. A total of 500 subjects with AAA will be included in the study, 250 in each study arm. Patients will be randomised to metformin or standard care in a 1:1 ratio. CT imaging and AAA US will be performed at baseline, 24 months and end of study, as well as if necessary according to clinical routine. Study drug will start at baseline and continue through completion. When all enrolled subjects have completed the 24-month follow-up (including imaging) an interim analysis will be performed to assess for efficacy and safety; if there is no trend towards a positive effect or signs of a harmful effect of metformin, the study will be stopped at this phase.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 500
• Est. completion date: January 2026
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Provision of written informed consent.

2. Male and female patients.

3. Age 50-80 years.

4. Documented AAA Ø 30-49 mm for men and 30-44 mm for women.

5. Fasting p-glucose <7.0 mmol/L. Fasting is defined as no caloric intake for =8 h.

Exclusion Criteria:

1. Short expected survival.

2. History of current or previous diabetes mellitus.

3. Current or previous use of metformin.

4. Not expected to tolerate metformin.

5. Contraindications to metformin treatment according to SmPC

6. Known or suspected connective tissue disorder (Marfans syndrome, etc), infected or inflammatory aneurysm, aneurysm development after aortic dissection or previous surgery of the infrarenal aorta.

7. Enrollment in either another investigational drug or medical device study or another investigational study of an approved drug or medical device within 30 days prior to enrollment of the current study.

8. If, in the opinion of the investigator, it is not in the patient's medical interest to participate in the study or the patient is unlikely to be able to comply with the study protocol.

9. Pregnancy.

Related Conditions & MeSH terms

• Abdominal Aortic Aneurysm
• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal

Intervention

Drug:
• Metformin
Metformin target dose 2 g daily

Other:
• Standard care
Abdominal aortic aneurysm surveillance

Locations

Country	Name	City	State
Sweden	Uppsala University Hospital	Uppsala	Sverige

Sponsors (1)

Lead Sponsor	Collaborator
Uppsala University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Abdominal aortic aneurysm (AAA) diameter growth rate	To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA diameter (mm) in patients with small AAAs who do not have diabetes.	5 years
Secondary	Abdominal aortic aneurysm (AAA) volume growth rate	To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA volume (ml) in patients with small AAAs who do not have diabetes.	5 years